Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C

Fattovich, A G; Giustina, G.; Degos, Françoise; Diodati, G.; Tremolada, F.; Nevens, Frederik; Almasio, Piero Luigi; Solinas, A; Brouwer, J.T.; Hc, Thomas; Realdi, G.; Corrocher, Roberto; Schalm, S W

doi:10.1097/00042737-199710000-00023

Cited by 34 publications

(52 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It has been described that patients with advanced chronic liver disease who achieved sustained virological response with interferon-based treatments have a hepatocellular carcinoma annual rate as low as 1% (6), while for untreated patients it is around 3% [5,6] . In terms of hepatic decompensation, it has been described an annual rate of 1.4% for patients treated with interferon, in opposition to a 5.7% for untreated cirrhotic patients [6] .…”

Section: Discussionmentioning

confidence: 99%

“…Only 37.8% of patients were naïve, and 11% had liver graft cirrhosis. All patients were Child-Pugh A class at the start of the treatment and the median MELD score was 7 (6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16). At the initiation of therapy, mean bilirubin level was 1.06 ± 0.27 mg/dL, mean platelet count was 117,788 ± 50,546/mm 3 , and mean albumin level was 4,140 ± 424 mg/dL.…”

Section: Baseline Characteristics Of Patientsmentioning

confidence: 99%

“…Around 16% of patients will develop cirrhosis after 20 years of infection [2] , although fibrosis progression can vary due to several factors such as age, alcohol consumption or hepatitis B or human immunodeficiency virus (HIV) co-infection [3] . Once cirrhosis is established, a yearly incidence of hepatocellular carcinoma of 1.4-3.4% [4][5][6] , and a yearly incidence of hepatic decompensation (including episodes of ascites, jaundice, hepatic encephalopathy or variceal bleeding) of 3.9-5.7% [4,6] has been reported.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

Berge¹,

Arencibía²,

Oton³

et al. 2017

View full text Add to dashboard Cite

Aim:The aim was to assess the clinical impact of direct-acting antiviral treatment in patients with compensated hepatitis C virus-related cirrhosis after one year of follow-up. Methods: An observational retrospective study was conducted on 129 consecutive patients with compensated cirrhosis treated in 2015, analyzing the evolution of liver function and the development of hepatocellular carcinoma and clinical decompensations. Results: The median follow-up time was 16 months. Most patients were males (73%), the mean age was 58.1 years and the most frequent genotype was 1b (52.2%). All participants were Child-Pugh A class at the start of the treatment and the median model for end-stage liver disease (MELD) score was 7. Four patients (4.4%) suffered a decompensation: three episodes of ascites and one acute on chronic liver failure. The incidence of de novo hepatocellular carcinoma during the follow-up was 3.6%. Seven patients (7.8%) improved MELD score more than one point and in 11 patients (12.2%) it worsened more than one point. There was a significant improvement in the mean platelets count [P < 0.001, 95% confidence interval (CI) : -26,360, -12,096] and in the mean albumin levels (P < 0.001, 95% CI: -322, -130) after treatment. Conclusion: Direct-acting antiviral treatment is not associated in the short term with a decrease in the development of hepatic decompensation or hepatocellular carcinoma compared to what it was reported for untreated compensated cirrhotic patients. There is an improvement in pre and post-treatment platelet counts and albumin levels showing a probable improvement of the hepatic function. Key words:Direct-acting antiviral therapy, compensated cirrhosis, hepatocellular carcinoma, clinical decompensation ABSTRACTArticle history:

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Baseline Characteristics Of Patientsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

Berge¹,

Arencibía²,

Oton³

et al. 2017

View full text Add to dashboard Cite

show abstract

“…This was calculated assuming a SVR rate of 15% and an incidence of HCC development of 0.5 per 100 person/years for SVR subjects and 2.4 per 100 person/years for non-SVR subjects. 19 …”

Section: Sample Size Calculationmentioning

confidence: 99%

Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study

et al. 2007

View full text Add to dashboard Cite

“…1 When untreated, chronic HCV infection can lead to cirrhosis, hepatocellular carcinoma, and end-stage liver disease. [2][3][4] Currently, the most effective therapy for chronic HCV infection is the combination of weekly subcutaneous injections of pegylated interferon-␣ (PEG-IFN) and daily oral dosing of ribavirin. Although this regimen has resulted in substantial improvements in the response rates compared to the earlier use of nonpegylated IFN with or without ribavirin, current treatments are only effective in approximately 50% of infected patients and are not suitable for many patients; most failures occur in patients infected with HCV genotype 1 or 4.…”

mentioning

confidence: 99%

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

et al. 2007

View full text Add to dashboard Cite

3) pg/ml increase (P < 0.01); and 2 5 -oligoadenylate synthetase (OAS) had a 163 (؎120.6) pmol/dl increase (P < 0.01). Decreases in HCV RNA also were dose-dependent, with the greatest group geometric mean maximum reduction of 1.69 ؎ 0.618 log 10 (P < 0.05) observed in the 0.75 mg/kg dose group. Decreases >1 log 10 were seen in 22 of 40 patients who received >1 mg CPG 10101, with 3 patients exceeding a 2.5-log 10 reduction.

show abstract

Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C

Cited by 34 publications

References 0 publications

Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

Clinical outcomes of direct-acting antiviral therapy in patients with compensated hepatitis C virus-related cirrhosis

Sustained virological response to interferon-α is associated with improved outcome in HCV-related cirrhosis: A retrospective study

Phase 1B, randomized, double-blind, dose-escalation trial of CPG 10101 in patients with chronic hepatitis C virus

Contact Info

Product

Resources

About